# RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

> **NCT04514653** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 146 (actual)

## Conditions studied

- Neovascular Age-Related Macular Degeneration (nAMD)

## Interventions

- **BIOLOGICAL:** Ranibizumab
- **GENETIC:** ABBV-RGX-314 Dose 1
- **GENETIC:** ABBV-RGX-314 Dose 2
- **GENETIC:** ABBV-RGX-314 Dose 3
- **DRUG:** Local Steroid
- **DRUG:** Topical Steroid
- **GENETIC:** ABBV-RGX-314 Dose 4

## Key facts

- **NCT ID:** NCT04514653
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-25
- **Primary completion:** 2026-08
- **Final completion:** 2027-02
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04514653

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04514653, "RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04514653. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*